CBX2 and acute myeloid leukemia: Mechanistically, in acute myeloid leukemia (AML) cell lines, CBX2 KD alters the expression of genes within the p38 MAPK pathway by inducing chromatin reorganization at these regulatory regions, thereby affecting AML cell survival.